Adoptive transfer of CTLA4-Ig-modulated dendritic cells improves TNBS-induced colitis

Lisiery Negrini Paiatto1, Fernanda Guimarães Drummond Silva2, Áureo Tatsumi Yamada3, Wirla Maria Silva Cunha Tamashiro4; Patricia Ucelli Simioni1, 4, 5, 6 *

1Department of Biomedical Science, Faculty of Americana, FAM, 13477-360, Americana, SP, Brazil
2Department of Food, School of Nutrition, Federal University of Ouro Preto, 35400-000, Ouro Preto, MG, Brazil.
3Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), 13083-862, Campinas, SP, Brazil.
4Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, UNICAMP, 13083-862, Campinas, SP, Brazil.
5Postgraduate Program in Biological Science (Cellular and Molecular Biology), Department of Biochemistry and Microbiology, Institute of Biosciences, Univ Estadual Paulista, UNESP, 13506-900 Rio Claro, SP, Brazil
6Department of Biomedical Science, Faculty of Americana, FAM, 13477-360, Americana, SP, Brazil.

Correspondence should be addressed to Patricia Ucelli Simioni psimioni@gmail.com

E-mail Address:
Lisiery Negrini Paiatto: lisy_paiatto@hotmail.com
Dendritic cells (DCs) play a crucial role in balancing immune responses, and in that sense the interactions between the B7-1 and B7-2 molecules expressed on DCs and CD28 and CTLA-4 on helper T cells are fundamental. While coupling of B7 and CD28 molecules activates immune responses, binding of B7 to CTLA4 results in its blockade. CTLA4-Ig fusion protein, a competitor molecule of the B7-CD28 interaction, has been used for the development of immunological tolerance both experimentally and in patients. Here, we evaluated the effects of adoptive transfer of bone marrow-derived dendritic cells (BMDCs) pulsed with CTLA4-Ig in TNBS-induced colitis. CTLA4-Ig-modulated BMDCs or naïve BMDC were administered intravenously to BALB/c mice prior to TNBS rectal instillation. Five days later, spleens and colon segments were removed for immunological and histological analysis. Our results showed that the
adoptive transfer of CTLA4-Ig-modulated BMDCs was able to reduce the severity of inflammation caused by the administration of TNBS, in view of tissue integrity and reduced leukocyte infiltration in the colon segments of the treated mice compared to controls. Non-specific spleen cell activation in vitro showed a reduction in the frequency of CD4$^+$ IL-17$^+$ T cells and CD4$^+$ IFN-γ$^+$ T cells as well as IL-9 secretion in cultures. To our knowledge, this is the first description of the beneficial effects of treatment with CTLA4-Ig modulated BMDC in experimental colitis.

**Keywords:** colitis, dendritic cell, immune modulation, CTLA4-Ig, tolerance, inflammation, inflammatory bowel disease.
1. Introduction

Two distinct signals are required for the activation of the adaptive immune response. The first signal is established by the binding of antigen-specific receptors on the surface of T lymphocytes (TCR) and antigenic fragments associated with MHC molecules on the surface of antigen-presenting cells (APCs). The second signal comes from the engagement between co-stimulatory molecules, among which the CD28 expressed on the surface of T lymphocytes and B7-1 (CD80) and B7-2 (CD86) on the surface of APCs are prominent. The low affinity interaction between CD80/CD86 and CD28 is essential to promote the activation, proliferation and survival of lymphocytes. The production of specific antibodies by B lymphocytes and the increase of phagocytic cell activities are the most evident results of this initial activation (1–4).

As the immune response proceeds and the antigen triggering this response is eliminated, a cell surface glycoprotein called CTLA4 (CD152) begins to be expressed at low levels in activated T cells. CTLA-4 binds with high affinity to the costimulatory molecules CD80 and CD86 in dendritic cells (DCs), thus initiating the reduction of the specific immune response(5–9).

Altered responses against self-antigens are at the origin of autoimmune diseases. Inflammatory bowel disease (IBD) is a group of immune-mediated diseases characterized by severe inflammation of the digestive tract (10). The etiology of IBD is still unknown, but the most plausible hypothesis is that it is due to the combination of genetic and environmental factors, particularly disturbances of the microbiota, leading to an aberrant inflammatory response of the host (11–13). Several immunomodulatory
drugs such as azathioprine and mycophenolate (inhibitors of T-cell proliferation),
monoclonal antibodies, such as OKT3 (depletes and blocks T cells), and cyclosporine,
tacrolimus and glucocorticoids (blockage of cytokine production) have been applied
with relative success in the control of autoimmune diseases. However, most of them can
lead to complications related to the onset of opportunistic infections as well as
nephrotoxicity. Due to the serious side effects of nonspecific anti-inflammatory drugs
and broad-spectrum immunosuppressive drugs routinely employed in the treatment of
autoimmune diseases, current studies are looking at ways to manipulate immune system
to reduce the need for these substances (10). Thus, new therapeutic approaches aimed at
inhibiting immune responses in a more natural way have been developed in the last two
decades. Among these new approaches, one of the best studied involves the use of
CTLA4-Ig, a competitor molecule of the B7/CD28 interaction. In principle, its use
would allow the development of immune tolerance to autoantigens by naturally
blocking the activation of specific T lymphocytes (14–19).

To test these approaches prior to being screened in humans, several experimental
models are available. In relation to IBD, experimental models of colitis induced by
chemical or biological agents that mimic the main characteristics of human disease are
currently used (20–22). Colitis induced by instillation of 2,4,6-trinitrobenzenesulfonic
acid (TNBS) in BALB/c mice, for example, generates a relatively mild inflammation of
the intestinal mucosa and slight weight loss, with reestablishment of the animal within a
few days after instillation. Such characteristics make this one of the experimental
models most used in the study of colitis modulators (23,24).
It is well known that DCs can interfere in the balance between immunity and tolerance. However, few clinical applications have been successful so far (25–27). On the other hand, some experimental studies have shown that CTLA4-Ig, a soluble chimeric fusion protein (CD152/Fc), can block the B7/CD28 signaling pathway by competition with CD80 and CD86 molecules expressed in DCs, thereby reducing responses autoimmune and graft rejection (16,28).

In this work, we evaluated the effects of the adoptive transfer of CTLA4-Ig-modulated bone marrow-derived dendritic cells (BMDC_{CTLA4-Ig}) on the inflammatory response observed in TNBS-induced colitis in BALB/c mice. BMDC_{CTLA4-Ig} and control BMDCs (BMDC_{naive}) were administered intravenously for three consecutive days prior to instillation of TNBS. Five days later, the spleen and colon segments were removed for immunological and histological analysis.

2. Material and methods

2.1. Animals

BALB/c female mice (20–25g) at four weeks of age were obtained from the Multidisciplinary Center for Biological Research (CEMIB) of the University of Campinas (UNICAMP), Campinas, SP, Brazil. They were maintained in specific pathogen-free environment at 25° C ±1 and photoperiod of 12/12 hours. Mice were fed with autoclaved Nuvilab CR-diet (Colombo, PR, Brazil) and water ad libitum for 2-4 weeks before being used in experiments. Mouse manipulation were carried out in accordance with the ‘Guide for the Care and Use of Laboratory Animals’, as promoted by the Brazilian College of Animal Experimentation (COBEA) and approved by the
Ethics Committee for Animal Experimentation of University of Campinas (CEUA/UNICAMP Protocol #3077-1). All experimental procedures were performed under anesthesia (ketamine and xylazine) and all efforts were made to minimize animal suffering. Each experimental group consisted of at least five animals. Assays were repeated at least two times. Mice were monitored daily for signs of colitis such as rectal swelling, rectal bleeding, soft stools as well as weight loss.

2.2. Bone marrow dendritic cells

Bone marrow dendritic cells (BMDCs) were generated from bone marrow precursors as described elsewhere. Briefly, bone marrow cells were flushed from femurs and tibias of naïve BALB/c mice with RPMI 1640 medium (Sigma) containing 10% fetal bovine serum (FBS, Cultilab, Brazil), 20 μg/mL gentamicin solution (Sigma). Bone marrow cells were seeded in six-well plates (Corning, USA) at a density of 2×10⁶ white cells/well in RPMI-10% FBS containing 20ng/mL mouse recombinant granulocyte macrophage colony-stimulating factor (mrGM-CSF) (Biosource, USA) and then incubated at 37°C in 5% CO₂. On days 3 and 6, the culture medium was replaced with fresh medium containing GM-CSF(29). On the eighth day of culture, the differentiated cells were collected, pelleted by centrifugation at 200 g, for 10 min, resuspended in RPMI-10% FBS containing 40ng/mL CTLA4-Ig (CD152/Fc chimera, non-cytolytic, from mouse, Sigma C4358), plated in 24-well culture plates at a density of 2 x 10⁶ cells/well and cultured for an additional 24 hours (BMDC_{CTLA4-Ig}). Cells cultured in the absence of CTLA4-Ig were used as control (BMDC_{naïve}).

2.3. Phenotypic profile of BMDC
The phenotypic characteristics of the BMDCs were evaluated by flow cytometry as previously described by our group (30) and others (31–33)(33). For this, the cells were labeled with anti-mouse CD11c-APC (Clone: HL3), anti-mouse MHC-II-PE (130-091-368, Miltenyi Biotec), anti-mouseCD80-FITC (Clone: 16-10A1), anti-mouseCD86-FITC (Clone: GL1) and anti-mouse CD40-FITC (Clone: 3/23) according to the manufacturer's instructions (BD Bioscience, USA). All controls were performed using irrelevant isotype staining. The readings were performed using the FACSCalibur (Becton-Dickinson, Franklin Lakes, NJ, USA) flow cytometer, using FCS Express 5 Plus, Research Edition software.

2.4. Adoptive transfer of BMDC and colitis induction

Three doses of 1x10^6 BMDC_{CTLA4-Ig} or BMDC_{naïve} were injected intravenously into naïve syngeneic mice on days 5, 3 and 1 before the colitis induction (Fig 1). Colitis was induced by intrarectal administration of a single dose of 2,4,6-trinitrobenzenesulphonic acid (TNBS), as described elsewhere, with modifications. Briefly, mice were anesthetized with and instilled with 100µL of 1.0mg/mL TNBS (2,4,6-trinitrobenzenesulfonic acid; Sigma, USA) dissolved in 50% ethanol into the lumen of the colon. To ensure that TNBS enter entire colon, mice were held in a vertical position for 30s. Two control groups of mice that did not receive DC were used: 1) animals inoculated intrarectally with 100µL 50% ethanol in saline; 2) animals inoculated intrarectally with 100µL of 1.0mg/mL TNBS dissolved in 50% ethanol.
2.5. Evaluation of clinical symptoms of TNBS-induced colitis

Animals of all groups were weighed daily until sacrifice on the fifth day following the instillation of TNBS. Weight variation was calculated as percentage, considering the weight at day zero as 100%. Clinical symptoms such as diarrhea, rectal prolapse, bleeding and cachexia were registered and assigned as scores, ranging from 0 to 2, with 0: no change, 1: slight change (liquid feces, inflammation in the anus, mucus liberation and weakness), and 2: severe change (diarrhea, rectal prolapse, bleeding, and cachexia) and these values were mean to each animal. Data are presented as the mean ± Standard Error of the Mean (S.E.M.)

2.6. Histological analysis of the colon

The mice were euthanized five days after induction of colitis. Two portions of the colon distant 1-2 cm (P1 = proximal1) and 2-3 cm (P2 = proximal 2), respectively, of the anal sphincter were removed, fixed in 4% buffered formalin, dehydrated with ethanol solutions, and embedded in paraffin (Paraplast Plus Sigma P3683). Slices of 5μm were cut into a microtome (Leica - model Jung Biocut 2035) and mounted on clean glass slides. The specimens were then dewaxed, rehydrated and stained with hematoxylin and eosin (Merck). As the distal portions of the intestine are unaffected by treatment with TNBS, sections of these segments were not examined.

The P1 and P2 segments of the colon were evaluated by microscopy for the presence of folds, hemorrhage, gauge and leukocyte infiltrate. The data were represented by scores corresponding to the sum of the values attributed to the presence and characteristics of the folds in the mucosa (0 for normal folds, 1 for slightly altered folds, 2 for deformed
folds, 3 for very deformed folds, 4 for dorsal folds reduction, 5 for lack of folds); bleeding (0 for no bleeding, 1 for bleeding present, 2 for large bleeding); mucosal dilatation (0 for absence of voids, 1 for apparent voids, 2 for large voids); and lymphocytic infiltrate in the mucosa, submucosa and mesentery (0-none; diffuse inflammatory infiltrate-1; 2-considerable inflammatory infiltrate with submucosal disorganization; 3-intense infiltrate) as previously described. Thickening of the colon wall was measured in micrometers using the Infinity Analyze Nikon H600L (100X). The final scores represent the mean ± S.E.M (23,34).

Histomorphometric analysis was performed on sections of P1 and P2 segments prepared for immunoperoxidase reactions using the following antibodies: anti-CD3 (T lymphocytes) and anti-F4/80 (macrophages) and anti-Ly-6c NIM (neutrophils) (35,36). Peroxidase-conjugated secondary antibodies (Sigma) and diaminobenzidine (DAB; Sigma) were used in the development of reactions (37,38). After counter-staining with hematoxylin/eosin, the tissues were observed under light microscopy for counting the labeled cells. Evaluations were done in a double-blind fashion and the quantification of labeled cells was performed in five random fields in each specimen. Sections P1 and P2 of at least three animals in each group were evaluated, making a total of 15 measurements per group, in each experiment. Results were expressed as mean ± S.E.M. Three independent experiments were performed (24,39,40).

2.7. Spleen cell proliferation

Spleens were collected aseptically from mice of all experimental groups, macerated individually, suspended in lyses buffer and pelleted by centrifugation at 200 g for 10
min. Cell concentrations were adjusted to $1 \times 10^6$ cells/mL in RPMI medium (Sigma, USA) supplemented with 10% fetal bovine serum (Cultilab, Campinas, Brazil). After washing, spleen cell suspensions were incubated with 25μM carboxyfluorescein succinimidyl probe ester (CFSE) in RPMI-10% FBS at room temperature for 5 min, according manufacturer’s recommendations (Invitrogen, USA). Cells were then pelleted by centrifugation and suspended in fresh medium. To determine the maximum uptake of CFSE, aliquots of each cell suspension were fixed with 1% formaldehyde in PBS and analyzed by flow cytometer. Then 100μL aliquots of each suspension of CFSE-labeled cells were seeded in duplicate in 96-well plates (Corning) and incubated in the presence of 2.5 μg/ml ConA for 72 hours at 37°C. Cultures of cells conducted in the absence of Con-A were used as controls.

The proliferation of T lymphocytes in the cultures was assessed at the gate of CD4+CFSE+ cells. Acquisitions were performed with FACSCalibur flow cytometer (FACSCalibur flow cytometer, BD Becton Dickinson, San Jose, CA)(34,41). The results were analyzed with the FCS Express Plus Research Edition software (FCS Express Launcher). Results were expressed as proliferation index (fold change) calculated in relation to that of the control group (24,34).

In parallel, cultures of CFSE-unlabeled spleen cells from mice of all experimental groups were conducted to measure the levels of cytokines released in the supernatants after Con-A stimulation as described below.

2.8. Phenotypic profile of T-cells

The frequencies of TCD4+CD25+ Foxp3+ (Treg cells), TCD4+IL17+, TCD4+IFNγ+ and
TCD4‘IL-10’ cells in the spleen cell cultures were assessed by flow cytometer. Briefly, cell suspensions were washed and initially stained with anti-CD3 APC (clone 145-2C11, BD #553066), anti-CD4-PE (Clone GK1.5) and anti-CD25-FITC (Clone 7D4). Then, cells were permeabilized by the addition of fixation/permeabilization buffer (Cytofix/Cytoperm fixation/permeabilization kit, Becton-Dickinson, BD). Suspension was stained with anti-Foxp3-APC (clone FJK-16S), anti-IL-17-APC (clone eBIO17B7) or Alexa Fluor 647 (Clone TC11-18410), anti-IFN-γ-APC (Clone XMG1.2) and IL-10-APC (Clone JESS-16E3), 647 (Clone Q21-378), according to manufacturer’s instructions. Controls were performed with irrelevant isotype staining. Acquisitions were performed with FACScalibur flow cytometer and analyzes were done with the FCS Express 5 Plus, Research Edition software (23,34)

2.9. Determination of Th1, Th2, Th17 and Th9 cytokines

IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ and TNF-α were quantified in culture supernatants of spleen cells by flow cytometer, using Multiplex CBA kit (BD Cytometric Bead Array Th1/Th2/Th17, San Diego, USA) according to manufacturer’s instructions. Fluorescence were acquired in FACSCalibur cytometer and analyzed with FCAP Array TM Software Version 3.0 (BD). IL-9 determination was assayed with CBA flex set (BD Cytometric Flex Set Th9, San Diego, USA) (23,34)

2.11. Statistical analysis

The statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). The statistical significance of differences between control and experimental groups were determined by one-way ANOVA, followed by Bonferroni’s
test for multiple comparisons or unpaired Student’s t-test. The results were expressed as mean ± Standard Error of the Mean (S.E.M). Values were considered significant at P<0.05. All data presented are representative of at least three independent experiments.

3. Results

The effects of adoptive transfer of BMDCs on TNBS-induced colitis

Dendritic cells were differentiated in vitro from precursors collected from the bone marrow of BALB/c mice by their culture in the presence of recombinant GM-CSF for eight days. Differentiated bone marrow DCs (BMDCs) were then incubated in the presence or absence of recombinant CTLA4-Ig for 24 hours before being employed in adoptive transfer assays. We observed that modulation of BMDCs with CTLA4-Ig did not modify the expression pattern of the CD11c, MHC class II, CD40, CD80 and CD86 molecules on the surface of these cells compared to CTLA4-Ig untreated BMDCs (BMDCnaïve), as can be seen in Supplementary Figure 1 (Supp. Fig 1).

Weight loss in TNBS-induced colitis is generally mild (about 10%) and recovery of body weight is usually observed as early as the fourth day after drug administration in BALB/c mice. As can be seen in Figure 2A, the adoptive transfers of BMDC_{CTLA4-Ig} or BMDC_{naïve} did not result in any significant improvement in weight loss observed in the first days after TNBS instillation and, as expected, by the fourth day all mice had already recovered. However, the other clinical signs of the disease (diarrhea, rectal prolapse, soft stools, and hemorrhagic stools) were significantly reduced by previous treatment with BMDC_{CTLA4-Ig}, as shown in Figure 2B.
274  [Insert Fig 2]

275  As can be seen in Figure 3A, administration of TNBS induced a strong inflammatory
276  reaction that affected the regions closest to the rectum (both P1 and P2 segments), with
277  a large number of infiltrated leukocytes. However, previous treatment with
278  BMDC_{CTLA4-Ig} significantly reduced leukocyte infiltration caused by instillation of
279  TNBS.

280  The cells present in the infiltrate consisted mainly of macrophages (Figure 3B), while
281  neutrophils were rarely found. It was also observed that the colonic tissue of mice
282  treated with BMDC_{CTLA4-Ig} showed a significant reduction in the number of infiltrated
283  macrophages when compared to the tissues of mice without previous treatment with
284  BMDCs. Pretreatment with BMDC_{naive} did not modify the inflammatory process
285  induced by the instillation of TNBS. On the other hand, the adoptive transfer of
286  BMDC_{CTLA4-Ig}, but not BMDC_{naive}, was able to prevent thickening of the colon wall,
287  particularly in the P1 region, as shown in Figure 3C.

288  [Insert Figure 3]

289  The effects of adoptive transfer of BMDCs on immune response of colitic mice

290  The effects of the adoptive transfer of BMDC_{CTLA4-Ig} on the immunological functions of
291  lymphocytes from colitic mice are shown in Figures 4 and 5. The proliferative response
292  of T lymphocytes was significantly lower in cultures of spleen cells from mice
293  pretreated with BMDC_{CTLA4-Ig} than in controls groups (Figure 4A). The frequencies of
294  Treg cells (CD25^{+} Foxp3^{+} T cells) in cultures of spleen cells of mice previously treated
with BMDC_{CTLA4-Ig} as well as those receiving TNBS alone were significantly higher than in the other groups, as shown in Figure 4B. The frequency of CD4^{+} T cells producing IFN-\(\gamma\) and IL-17 was significantly lower in the cultures of spleen cells from mice pretreated with BMDC_{CTLA4-Ig}, compared to the other groups (Fig 4, C and E). On the other hand, the frequency of CD4^{+} T cells producing IL-10 was higher in the cultures of spleen cells from mice pretreated with BMDC_{CTLA4-Ig} and, interestingly, lower in the cultures of spleen cells from mice pretreated with BMDC_{naive} compared with the other groups (Figure 4G). No significant differences were observed between the experimental groups in relation to the intracellular labeling of RORc and T-bet transcription factors (Fig 4D, 4F). However, GATA3 factor labeling was higher in spleen cells from mice treated with BMDC_{CTLA4-Ig} (Fig. 4H).

As shown in Figure 5C, IL-4 was present at levels detectable only in spleen cell culture supernatants from mice pretreated with BMDC_{CTLA4-Ig}. Significantly elevated IL-10 levels were found in supernatants from splenic cell cultures of mice pretreated with BMDC_{naive} or BMDC_{CTLA4-Ig}, compared to controls (Figure 5E). However, IL-6 levels were also higher in spleen cultures from BMDC_{naive}-pretreated mice compared to the other groups (Figure 5B). Higher IL-9 levels were detected in splenic cell culture supernatants from control mice that received only intrarectal ethanol. In mice treated with BMDC_{CTLA4-Ig} prior to TNBS instillation, however, levels of IL-9 were significantly lower than in all other groups (Figure 5G). There were no significant differences in the levels of IL-2, IL-17, TNF-\(\alpha\) and IFN-\(\gamma\) (Figure 5 A, D, F, H, respectively).

[Insert Figures 4 and 5]
4. Discussion

Experimental colitis induced by TNBS instillation is characterized by chronic inflammation of the gastrointestinal tract of mice with features overlapping those seen in inflammatory bowel diseases in humans. Literature data have shown the importance of oral tolerance and treatments with tolerogenic dendritic cell for the reduction of colitis damages. In this sense, previous studies of our group have shown that oral tolerance to OVA albumin as well as the adoptive transfer of dendritic cells from OVA-tolerant mice is able to reduce the damage caused by TNBS-induced colitis in syngeneic animals (23,24). We have also shown that flaxseed protein hydrolysates and phenolic fractions were able to ameliorate TNBS-induced colitis in BALB/c mice. Treatments with flaxseed protein fractions reduced inflammation of the intestinal mucosa in TNBS-induced colitis in BALB/c mice, as well as the proliferation of their splenic cells in response to Con-A, the frequency of Th1 and Th17 cells, and the levels of inflammatory cytokines in culture supernatants. In addition, the administration of phenolic compounds from flaxseeds prevented intestinal inflammation and increased the frequency of Treg lymphocytes in splenic cell cultures of BALB/c mice with colitis (34). The present work expanded these findings, demonstrating that the adoptive transfer of bone marrow-derived dendritic cells modulated with CTLA4-Ig, a recombinant mouse protein which binds with both B7-1 and B7-2 molecules, can improve clinical signs of the TNBS-induced colitis in BALB/c mice. It also shows that after transfer of CTLA4-Ig-modulated BMDCs, spleen T lymphocytes from mice with colitis show a more reduced proliferative response to Con-A accompanied by a reduction in the frequency of inflammatory cells secreting IL-17 and IFN-gamma as well as expansion of cells that produce IL-10 in the cultures. Our data showing an improvement in colitis with
CTLA4-Ig-modulated BMDCs corroborates with previous data showing that adoptive transfer of DCs modulated with dexamethasone and Vitamin D3 (42,43) or IL-10-modulated DC (44) protects severe combined immune deficient (SCID) mice from weight loss and pathologies associated with wasting diseases and colitis.

CTLA4-Ig is able to selectively modulate T cell activation by binding to CD80/CD86 costimulatory molecules in DCs (9,45). It is already known that direct administration of CTLA4-Ig affects the functioning of DCs through the IDO pathway, promoting a regulatory phenotype and consequently inducing the increase in the population of CD4⁺CD25⁺Foxp3⁺ T cells (9,46,47). In the murine model of arthritis, treatment with CTLA4-Ig was able to reduce the expression of CD80/CD86 molecules on DC and suppressed the inflammatory response associated with the disease (47). Our results did not show significant changes in CD80 and CD86 expression after the BMDCs were treated with CTLA4-Ig. This may be related to the origin of dendritic cells, i.e. differentiated dendritic cells from bone marrow precursors, and to the doses of CTLA4-Ig used in this work. Moreover, we used the recombinant protein to modulate the BMDCs to be transferred adoptively to mice rather than administering it directly to the animals.

It is well known that the instillation of TNBS causes severe changes in the distal portion of the large intestine, due to the inflammatory process triggered by the immune response to the drug. Administration of TNBS to rats, for example, results in increased expression of fibrosis-associated proteins such as phospho-p38, phospho-SMAD2/3, and PPARγ (48). In agreement with previous studies, we observed that the instillation of TNBS caused significant histological changes in the large intestine segments of
BALB/c mice, particularly in the P2 segment (2 to 3 cm of the anal sphincter). These changes were characterized by a thickening of the colon and intense inflammatory infiltrate consisting mainly of macrophages.

The literature shows that in the TNBS-induced colitis the adaptive immune response is predominantly Th1 type, characterized by an increase in IFNγ-producing T cells. In protocols for weekly administration of TNBS for six consecutive weeks, an influx of T cells was observed around the third day to two weeks after instillation of the drug, infiltrating the lamina itself and the submucosal layer of the large intestine and supporting chronic colitis (49). In TNBS single-dose protocols such as that used in this study, lymphocyte migration to the lamina propria begins about one week after instillation of the drug (50). Since the animals were euthanized on the fifth day after TNBS administration, this cell type was virtually absent in our histological preparations. Likewise, a reduced number of neutrophils were observed in P1 and P2 preparations since the maximum migration of these cells occurs within the first 48 hours after the instillation of TNBS. As expected, in the time elapsed between administration of TNBS and the euthanasia of the animals for histological analysis, macrophages were the most abundant cells in the inflammatory infiltrate, particularly in the P2 segment of the colon of animals receiving TNBS alone, in a typical hypersensitivity reaction, as described in figures 3.

Our results show that the adoptive transfer of CTLA4-Ig-modulated BMDC was able to significantly prevent colon thickening in the P2 portion of the large intestine as well as the infiltration of macrophages in response to instillation of TNBS. Data from the literature indicate that the intense leukocyte infiltrate in the intestinal mucosa may be
Lesions in the colon mucosa may be associated with the release of significant amounts of free radicals, due to the abundance of activated macrophages attracted to the lesion site (52,53). Thus, our results indicate that DCs modulated in vitro with the recombinant CTLA4-Ig protein constitute at least one more natural therapeutic alternative for the treatment of these disorders.

In order to evaluate the influence of the adoptive transfer of CTLA4-Ig-modulated BMDCs on the immune response of TNBS-treated mice, we examined the proliferative responses, the effector CD4$^+$ T cell profiles and the release of cytokines in cultures of spleen cells collected on the fifth day after induction of colitis and stimulated in vitro with Con-A. Data presented here (Fig 4) show that spleen cells from animals of all groups proliferated in response to Con-A, but such ability was significantly lower in splenic cells from mice pretreated with CTLA4-Ig-modulated BMDCs.

Examination of effector CD4$^+$ T cell populations in splenic cell cultured in the presence of Con-A showed that treatment with BMDC$_{CTLA4-Ig}$ resulted in a significant reduction in the frequency of IL-17$^+$ and IFN-γ$^+$ cells and in the elevation of CD4$^+$ IL-10$^+$ and CD4$^+$ Foxp3$^+$ T cells. Frequency of GATA-3 expressing cells was higher in the splenic cell cultures of mice treated with CTLA4-Ig modulated BMDCs. However, TCD4$^+$ cells expressing the Th1/Treg cell associated RORc and T-bet transcription factors did not show significant variations between the different treatments.

Treg cells play a key role in the control of immune responses to autoantigens as well as on those that act upon pathogens, commensals, tumors, and grafts. Such control is
exerted by the ability of Treg cells to accumulate in inflamed areas and to adapt to the environment, being particularly critical in tissues repeatedly exposed to the presence of microbes and environmental aggressions such as the gastrointestinal tract and skin (54,55). It has been shown that the canonical Th2 transcription factor GATA3 is selectively expressed in Treg residing in barrier sites including the gastrointestinal tract and the skin, being fundamental to maintain high levels of Foxp3 expression in various polarized or inflammatory settings (56). Corroborating these data, we observed a significantly higher frequency of Treg cells in spleen cell cultures from mice receiving only TNBS and those from mice pretreated with BMDC\textsubscript{CTLA4-Ig}. However, a significant increase in cells expressing both Foxp3 and GATA-3 was observed only in the group that received BMDC\textsubscript{CTLA4-Ig}, indicating its influence in promoting a more efficient control of the inflammatory response induced by TNBS.

Although the frequencies of IL-17 and IFN-γ-secreting T cells were reduced in splenic cell cultures of mice pretreated with BMDC\textsubscript{CTLA4-Ig}, no significant differences were observed in the levels of these cytokines in spleen cell culture supernatants from mice pretreated with either BMDC\textsubscript{CTLA4-Ig} or BMDC\textsubscript{naïve}. On the other hand, IL-4, whose production is controlled by GATA-3 expression, was detected only in spleen cell cultures of BMDC\textsubscript{CTLA4-Ig} treated mice. In the spleen cell cultures from mice pretreated with BMDC\textsubscript{naïve} it was possible to observe the higher levels of IL-6, but it was also the one that presented the highest levels of IL-10, whose production is controlled by the transcription factor Foxp3. Thus, while splenic cell cultures of BMDC\textsubscript{CTLA4-Ig} pretreated mice had higher levels of IL-4, those of mice pretreated with BMDC\textsubscript{naïve} had higher levels of IL-10. The significance of these findings still needs further investigation.
The presence of cells expressing the transcription factor PU.1, a regulator of the
development of Th9 cells, has been observed in the intestinal lamina propria of patients
with ulcerative colitis and Crohn's disease (57). Although we did not examine the
frequency of Th9 cells in the splenic cell cultures of the different groups studied here,
we found that the production of IL-9 in the supernatants of the spleen cell cultures from
mice treated with BMDC_{CTLA4-Ig} was significantly more reduced than in other cell
cultures, including those from mice that received only the vehicle.

IL-9 is a cytokine that may act differently on Th17 cells or Treg cells, as an inducer or
regulator of tissue inflammation. IL-9 associated with TGF-β may drive the
differentiation of Th17 cells. In turn, Th17 cells can secrete IL-9, which affects
inflammatory response \textit{in vivo}. IL-9 also acts \textit{in vitro} on FoxP3^{+}CD4^{+} Treg cells,
increasing their suppressive function. This activation occurs by signaling pathways
associated with transcription factors STAT3 and STAT5 (58).

Reports show that in addition to cytokines released by Th1 and Th17 cells, IL-9 is also
involved in T cell-mediated experimental colitis, promoting mucosal ulceration and
chronic inflammation. In this way, Th9 cells represent a potential target for the
treatment of chronic intestinal inflammation (22,59).

It is known that acute and chronic intake of alcohol produces sensitive changes in the
intestinal mucosa, contributing to the installation or worsening of IBD already installed,
both in humans and in experimental models (60). The literature, however, does not
report on possible changes due to the use of 50% alcohol as a control of the instillation
of TNBS dissolved in this vehicle. However, we have observed that the instillation of
50% ethanol is not as innocuous as its use has resulted in some changes of an inflammatory nature such as elevated TNF-α, IL-9 and IL-17 levels in the corresponding splenic cell cultures, although important differences were observed in the instillation of TNBS/50% ethanol compared to ethanol instillation alone.

The blockade of the CTLA4 molecule is already described as a potential therapy for tumor treatment (61–63). However, studies related to the blockade of this molecule by the direct administration of CTLA4-Ig for the treatment of inflammatory bowel diseases did not present promising results (64). In this context, the use of CTLA4-Ig-modulated dendritic cells, instead of the direct application of this inhibitor, may be a clinical alternative to treat patients with IBD. Studies have shown that the CTLA4-Ig fusion protein affects the functioning of DCs through the IDO pathway, promoting a regulatory phenotype in this population (9,26,47). Dendritic cell therapies for immunomodulation have been presented as a therapeutic option under study, due to the great advance in the use of these cellular populations in the treatments of autoimmune diseases (65,66).

Wang and colleagues observed that BMDCs generated from mouse bone marrow and stimulated with GM-CSF have a mature DC cell profile and can be used in antitumor immunity studies. Adherent cells from these cultures have macrophage properties and may be used to induce tolerance, whereas mixed cells may potentiate tolerogenicity or pro-tumorigenic responses. Immature DCs have a strong migration and capture capabilities, while mature DCs activate naïve T cells and express high levels of costimulatory adhesion molecules and cytokines (67).

Taken together, our results allow us to conclude that adoptive transfer of CTLA4-Ig-modulated BMDC improves clinical signs of TNBS-induced colitis. Histological
analysis of intestinal segments showed that the adoptive transfer of CTLA4-Ig-modulated BMDC reduced the infiltration of inflammatory cells, particularly macrophages, and improved tissue damage in the colon. Adoptive transfer of CTLA4-Ig-modulated BMDC was also able to alter the immunological profile of activated splenic cells in vitro. Spleen cell culture of CTLA4-Ig-modulated BMDC-pretreated mice showed a reduction in the frequency of CD4+ T cells producing IFN-γ and IL-17 and IL-9 secretion, as well as increased frequency of Treg cells and IL-10 production. To our knowledge, this is the first description of the beneficial effects of treatment with CTLA4-Ig modulated BMDC in experimental colitis at the histological and immunological level.

**Data Availability**

The research data used to support the findings of this study are included within the article.

**Conflict of Interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding Statement**

Grant (#2013/20258-2) and fellowships (#2014/16701-0, #2014/08591-0, #2014/086192, #2015/09326-1) were obtained from São Paulo Research Foundation (FAPESP) and Coordination for the Improvement of Higher Education Personnel (CAPES).
REFERENCES


Jan 7 [cited 2015 Jan 10];21(1):21. Available from:
ntrez&rendertype=abstract

ntrez&rendertype=abstract


http://www.ncbi.nlm.nih.gov/pubmed/18667318%5Cnhttp://ac.els-cdn.com/S0966327408000294/1-s2.0-S0966327408000294-


30. Simioni PUPUU, Fernandes LGRGRLG, Tamashiro WMWMSCMWM. Downregulation of L-arginine metabolism in dendritic cells induces tolerance to exogenous antigen. Int J Immunopathol Pharmacol [Internet]. 2017 Nov 30 [cited


34. E Silva FGD, Paiatto LN, Yamada AT, Netto FM, Simioni PU, Tamashiro WMSC. Intake of Protein Hydrolysates and Phenolic Fractions Isolated from Flaxseed Ameliorates TNBS-Induced Colitis. Mol Nutr Food Res [Internet]. 2018 Aug 9 [cited 2018 Aug 16];e1800088. Available from:


47. Ko HJ, Cho M La, Lee SY, Oh HJ, Heo YJ, Moon YM, et al. CTLA4-Ig

ntrez&rendertype=abstract

http://www.jimmunol.org/content/179/10/6988.full

ntrez&rendertype=abstract


dntrez&rendertype=abstract


Figures

Figure 1

A  BMDC generation

Bone marrow cells in RPMI+GM-CSF

Cell harvesting and culturing in the presence or absence of CTLA4-lg

0  3  6  8  9  Days

Fresh medium  Fresh medium  Recovery

B  BMDC administration and colitis induction

Intravenous administration of BMDC_{CLTA4-lg} or BMDC_{native}

-5  -3  -1  0  5  Days

Instillation of TNBS  Sacrifice
Figure 2:

A

B

Saline
TNBS
TNBS+BMDC_{naïve}
TNBS+BMDC_{CTLA4-Ig}

Clinical scores

0.0
0.2
0.4
0.6
0.8

Ethanol
TNBS
TNBS+BMDC_{naïve}
TNBS+BMDC_{CTLA4-Ig}

Weight (%)
Figure 3:

(A) Histological images showing the effect of different treatments on colon thickness and macrophage infiltration in P1 (1 to 2 cm) and P2 (2 to 3 cm) regions.

(B) Quantitative analysis of colon thickness and macrophage infiltration in P1 (1 to 2 cm) regions.

(C) Quantitative analysis of colon thickness and macrophage infiltration in P2 (2 to 3 cm) regions.

Figure 4:

The images and graphs illustrate the effects of various treatments on colon thickness and macrophage infiltration, showing significant differences (*) in the treated groups compared to the control group (Saline).
Figure 5

- Ethanol
- TNBS
- TNBS+BMDC<sub>naive</sub>
- TNBS+BMDC<sub>CTLA4-Ig</sub>

A. Proliferation Index

B. CD4+CD25+FoxP3+ cells (%)

C. CD4+IL17+ (%)

D. CD4+RORc+ (%)

E. CD4+IFN<sub>γ</sub>+ (%)

F. CD4+Tbet+ (%)

G. CD4+IL10+ (%)

H. CD4+GATA3+ (%)

Figure 5
Supplementary figure 1
CD11c+MHCII+ (MFI)

BMDC$_{\text{naive}}$

BMDC$_{\text{CTLA4-Ig}}$

CD11c+MHCII+ (%)

BMDC$_{\text{naive}}$

BMDC$_{\text{CTLA4-Ig}}$

CD11c+MHCII+CD80+ (MFI)

CD11c+MHCII+CD86+ (MFI)

BMDC$_{\text{naive}}$

BMDC$_{\text{CTLA4-Ig}}$